J&J Modifies Procrit Pricing Practices To Compete With Amgen’s Aranesp
Executive Summary
Johnson & Johnson is modifying its pricing practices for Procrit (epoetin alfa) to compete with Amgen's Aranesp (darbepoetin alfa)
You may also be interested in...
J&J Draws Line On Procrit Price; Will Not Meet Amgen Aranesp 40% Discount
Johnson & Johnson will not be matching Amgen's latest discounts in the EPO market, J&J CFO Robert Darretta indicated during an April 13 investor call
J&J Draws Line On Procrit Price; Will Not Meet Amgen Aranesp 40% Discount
Johnson & Johnson will not be matching Amgen's latest discounts in the EPO market, J&J CFO Robert Darretta indicated during an April 13 investor call
J&J Procrit Pricing Practices Stabilize Sales, Position Product For Rebound
J&J pricing strategies have stabilized Procrit sales, possibly positioning the struggling franchise for a rebound, CEO William Weldon stated